The only FDA-Approved treatment for Lysosomal Acid Lipase Deficiency (LAL-D)

KANUMA^® (sebelipase alfa) is a prescription medication used to treat people with a diagnosis of LAL-D.

Kanuma^® (sebelipase alfa) is administered via infusion

KANUMA is indicated for the treatment of people with a diagnosis of LAL-D and is administered as an infusion by a healthcare professional.

For more information on KANUMA infusions:

Download Infusion Brochure

Getting Started on Kanuma

KANUMA is indicated for the treatment of patients with a diagnosis of LAL-D. Once your doctor has determined that KANUMA is right for you, sign up for OneSource™, a personalized patient support program from Alexion Pharmaceuticals.

There are 2 ways to get access to OneSource:

Call 1-888-765-4747

Get in touch with a OneSource nurse case manager.

Download the OneSource enrollment form below

Print this form, sign it, and submit it to OneSource. Someone will be in touch within the next business day.

Submit via email: OneSource@alexion.com

Submit via fax: 1-800-420-5150

Download OneSource enrollment form

KANUMA support by OneSource

Once your doctor has decided that KANUMA is right for you, OneSource is here to help. After signing up, you will be matched with a dedicated Alexion nurse case manager who can help answer any questions you may have about KANUMA or LAL-D.

OneSource is staffed by Alexion nurse case managers who provide one-to-one education, information on funding options and access to KANUMA, and ongoing treatment support for people living with LAL-D, and their caregivers.

Our Nurse Case Managers provide personalized support:

Assistance from a dedicated nurse case manager
Answers to questions about LAL-D or KANUMA
Resources and education on the infusion process
Help connecting patients with other families affected by LAL-D

The Alexion Commercial Co-pay Program can limit out-of-pocket expenses to $5 for eligible patients with commercial insurance

OneSource nurse case managers can also help navigate the insurance approval process for benefits investigation and coverage

Get connected with your

OneSource nurse

case manager

1-888-765-4747

Monday through Friday,

8:30 AM to 5 PM (ET)

KANUMA^® (sebelipase alfa) INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION:

KANUMA (sebelipase alfa) is indicated for the treatment of patients with a diagnosis of lysosomal acid lipase deficiency (LAL-D).

IMPORTANT SAFETY INFORMATION:

Life-threatening and severe allergic reactions may occur in people who receive KANUMA. These reactions may occur in people who are starting treatment with KANUMA or in people who have previously received KANUMA without having an allergic reaction. Seek immediate medical care right away if you have any of the following signs or symptoms:

Chest pain or discomfort
Wheezing or trouble breathing
Rash or hives
Red eyes
Swelling of eyelids
Rapid heartbeat
Rapid breathing
Runny nose

Tell your doctor if you have had a severe allergic reaction to eggs or egg products, as people with a known history of egg allergies were excluded from clinical trials.

The most common side effects in patients treated with KANUMA are:

In infants with rapidly progressive disease presenting within the first 6 months of life: diarrhea, vomiting, fever, stuffy or runny nose, low hemoglobin (red blood cells), cough, swelling of the nose and throat, and hives.
In pediatric and adult patients: headache, fever, sore throat, swelling of the nose and throat, weakness, constipation, and nausea.

Tell your doctor if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.

These are not all of the possible side effects of KANUMA. Call your healthcare provider for medical advice about side effects. To report suspected side effects contact Alexion at 1-844-259-6783 or the FDA at 1-800-FDA-1088.

For additional Important Safety Information, please see the full Prescribing Information for KANUMA.

IMPORTANT SAFETY INFORMATION

Life-threatening and severe allergic reactions may occur in people who receive KANUMA...

Please see full Prescribing Information for KANUMA.